Cencora COR
Healthcare · Medical - Distribution · Synthos Deep Dive · 2026-07-03
The Overview
Cencora (formerly AmerisourceBergen) is one of the three giant middlemen that buy medicines from drugmakers and deliver them to pharmacies, hospitals and doctors' offices across the US and abroad. It is a plumbing business: enormous sales ($321 billion a year) but it keeps only about 1 cent of profit per dollar of sales. It wins by moving staggering volumes at razor-thin margins with brutal efficiency.
Is the stock cheap or expensive? Modestly cheap. It has fallen about 21% from its high and trades at a below-market multiple of next year's profit. Our estimate of fair value (~$340) is about 15% above today's price, and Wall Street's average target ($379) is higher still.
Our verdict is Buy — Tactical: a reasonable value holding, but not a get-excited, back-up-the-truck idea. Note plainly: no outside experts in our knowledge base cover this stock, so this call rests entirely on the numbers.
Here is what the three scores mean in everyday terms:
- Downside Risk 4/10 (fairly low). The stock is defensive — people need medicine in any economy — and it doesn't swing much. But the company carries meaningful debt after a big 2026 acquisition, and its margins are so thin there's little cushion if anything goes wrong.
- Growth Quality 5/10 (average). It grows profits at a decent mid-teens clip, but much of that comes from buying back shares rather than the underlying business booming, and the returns it earns are modest.
- Exponential Potential 3/10 (low). This is a steady utility, not a rocket. Sales creep up ~4% a year and are slowing — do not expect it to double quickly.
The one big worry: because margins are paper-thin, a squeeze on distribution fees, a bad opioid-litigation development, or a debt-servicing problem would hurt far more than it would at a fat-margin business.
Putting a number on it: our fair-value estimate is $340 against a current price of $322.03 — real upside if our numbers are right.
Our summary metrics
Low beta (0.59), defensive demand & 16.7× fwd EPS — but net-debt/EBITDA 2.0× post-OneOncology and razor-thin 3.5% gross margin.
~15% fwd adjusted-EPS CAGR on buybacks + mix, but sub-1% net margin and a distribution model with structurally low ROIC.
Decelerating ~4% revenue growth, $57B cap on a low-margin utility — a compounder, not an exponential.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, We don’t publish a reverse-DCF cross-check for pre-profit companies — negative or missing earnings break that math — so take this number on our modeling alone.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Decelerating ~4% revenue growth, $57B cap on a low-margin utility — a compounder, not an exponential.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $378.57 (high $440 / low $331; 33 Buy · 12 Hold · 1 Sell) — context, not our anchor |
| Valuation | 37× GAAP TTM EPS · ~16.7× FY26E adj · 15.0× FY27E adj · 9.6× FY30E adj · EV/S 0.21× · EV/EBITDA 13.6× |
| Technicals | Mixed — $296.51, −21% off 52-wk high, below 200-DMA, above 50-DMA, RSI 66, +0.4% 12-mo (SPY +20.6%) |
| Conviction | Low — 0 net-bullish voices, 0 KB claims; call rests entirely on fundamentals + quant |
| Position sizing | Satellite / value sleeve, ~1–3% — a defensive holding, not a core conviction bet |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for COR — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $322.03, 5% above the 50-day average ($307), 0% below the 200-day average ($323) — a mixed trend. 14% below the 52-week high of $375, 27% above the 52-week low of $253.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $322.03 is currently inside the band (band $305–$333).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 56.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.19, negative momentum.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = COR · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Cencora, Inc. (NYSE: COR) — renamed from AmerisourceBergen in August 2023 — is a global sourcing-and-distribution giant for pharmaceutical products, founded in 1871 and headquartered in Conshohocken, PA. It is one of the "Big Three" US drug distributors (with McKesson and Cardinal Health), an oligopoly that moves the vast majority of prescription drugs in the country. Fiscal year ends September 30.
The business is deceptively simple and structurally low-margin: buy drugs from manufacturers, warehouse and deliver them to acute-care hospitals, health systems, retail/mail-order/long-term-care pharmacies, clinics and physician practices, and layer on services (pharmacy management, specialty/oncology distribution, packaging, data analytics, clinical-trial logistics, animal health). Scale, logistics density and working-capital efficiency are the whole game.
Revenue mix (FY2025, from filings):
- By segment: Pharmaceutical Distribution $285.3B (88.8%) · International Healthcare Solutions $30.4B (9.5%) · Animal Health $5.7B (1.8%).
- By reporting geography: U.S. Healthcare Solutions $291.0B (90.5%) · International Healthcare Solutions $30.4B (9.5%). The book is overwhelmingly US.
The most important recent event: in February 2026 Cencora acquired OneOncology (a community-oncology platform), which drove goodwill from ~$9.3B to ~$13.7B, added ~$3.9B of net debt-funded consideration, and is management's stated lever to lift the U.S. Healthcare Solutions gross margin and deepen the high-value specialty/oncology franchise.
2. The expert thesis — why the panel is bullish (traceable)
There is no expert coverage of Cencora in the Synthos knowledge base. total_claims = 0, net_bullish_voices = 0. No conviction voice — bullish, bearish or neutral — has been distilled for this name.
That is stated plainly and honestly: this verdict is fundamentals- and quant-driven, with zero borrowed conviction. There are no claim_id values to cite because none exist. Readers should weight this note accordingly — it reflects the numbers and the analyst's framework, not a panel of independent experts. (For contrast, our high-conviction notes cite dozens of reconciled claims; this one intentionally cites none because inventing them would violate the house honesty standard.)
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 4 · Low-Moderate | Beta 0.59, defensive non-cyclical demand and ~16.7× forward adjusted EPS keep valuation risk contained; offset by net-debt/EBITDA ~2.0× post-OneOncology, a razor-thin 3.5% gross / <1% net margin, and residual opioid-litigation overhang. |
| Growth Quality | 5 · Average | ~15% forward adjusted-EPS CAGR, but heavily buyback/mix-assisted; sub-1% net margin and a low-ROIC distribution model. ROIC ~11.9% and ROCE ~16.5% are respectable for the model but not elite. |
| Exponential Potential | 3 · Low | Revenue growth ~4% and decelerating; a $57B low-margin logistics utility with a large but slow-growing TAM. A compounder-lite, not an exponential. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them. All EPS figures below are adjusted (non-GAAP) — the metric management guides to and the Street models, because GAAP is distorted by acquisition remeasurement gains and amortization.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | OneOncology accretes faster; specialty mix lifts gross margin; buybacks continue; FY27E adj. EPS beats to ~$21. Multiple re-rates to ~19×. | ~$400 (+35%) |
| Base (our anchor) | Estimates roughly hit — FY26E adj. EPS $17.79, FY27E $19.81; a steady low-teens/mid-teens compounder earns a ~17× forward multiple. | ~$340 (+15%) |
| Bear | Distribution-fee compression, an opioid-liability flare-up, or a debt/rate drag; adj. EPS growth stalls near $17. Multiple de-rates to ~14–15×. | ~$255 (−14%) |
Synthos fair value = the base case, ~$340 (+15%), with the full $255–$400 span as the honest range. This anchor sits below the Street's $378.57 consensus (we apply a more conservative multiple to a thin-margin distributor) and our bear is below the Street's $331 low. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). COR is neither an exponential nor an elite compounder — it is a defensive, low-margin distribution utility:
- Forward growth: revenue CAGR FY25→FY30E ~3.7% ($321B → $385B); adjusted-EPS CAGR FY26→FY30E ~14.9% ($17.79 → $31.04) — the gap between the two is the whole story: EPS grows ~4× faster than revenue via buybacks, margin mix and operating leverage, not underlying volume acceleration.
- Acceleration (the 2nd derivative) is negative on the top line: reported revenue grew +9.3% (FY25) but organic momentum is far lower — Q2 FY26 revenue was up just +3.8% YoY, and consensus models ~4% forward. The top line is decelerating, not accelerating. There is no inflection to ride.
- Room to run: the US drug-distribution TAM is enormous, but it is a mature, share-stable oligopoly growing roughly with drug spend (mid-single digits). At $57B market cap on <1% net margins, there is no realistic path to a multibagger from category expansion; the upside is incremental margin mix (specialty/oncology/GLP-1 volume) and capital return.
- Reinvestment runway: modest, disciplined capex (~$0.67B/yr) and negative cash-conversion-cycle working-capital economics (it collects from customers before paying suppliers) throw off strong FCF (~$3.2B FY25), which funds buybacks and M&A rather than high-return organic reinvestment.
Exponential Potential: Low (3/10). Own COR for defensive stability and modest capital-return-driven EPS compounding, not for growth. This honest framing is why it lands in the value/satellite sleeve, not the exponential tier.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $321.3B, +9.3% (FY24 $294.0B, +12.1% on FY23 $262.2B). Massive scale; growth is volume-and-price of drug spend, decelerating to ~4% most recently.
- Quarterly trajectory: Q2 FY25 $75.5B → Q3 $80.7B → Q4 $83.7B → Q1 FY26 $85.9B → Q2 FY26 $78.4B (+3.8% YoY). Sequentially lumpy; YoY growth has cooled to low-single-digits.
- Margins (the defining feature): gross ~3.5% TTM, operating ~1.3%, net ~0.78% TTM. This is the distribution model — pennies on huge volume. Management's Q2 FY26 release cites a 45–52 bp gross-margin lift from the OneOncology specialty mix, partly offset by lower-margin GLP-1 volume.
- Earnings: FY25 GAAP net income $1.55B, GAAP diluted EPS $7.96. GAAP is noisy (a $1.1B OneOncology remeasurement gain inflated Q2 FY26 GAAP EPS to $8.40) — adjusted diluted EPS is the honest gauge: $4.75 in Q2 FY26, +7.5% YoY, on track to FY26 guidance of $17.65–$17.90.
- Cash flow: operating CF $3.88B FY25, capex only −$0.67B, FCF ~$3.21B — a cash machine relative to reported net income (income quality/FCF benefits from negative working-capital cycle). FCF funded ~$4.3B of acquisitions (OneOncology), $0.44B dividends and $0.44B buybacks in FY25.
- Balance sheet: total debt $10.75B, net debt $6.35B, net-debt/EBITDA ~2.0× (up from ~1.0× a year ago — the OneOncology debt raise). Investment-grade but leverage stepped up; management is prioritizing debt paydown before resuming its stated $1B buyback by end-CY2026. Equity is thin ($1.5B) and ROE optically huge (116%) purely because the equity base is small — not a meaningful signal here.
6. Valuation — priced in or room?
On the honest (adjusted) numbers, COR is modestly cheap, not a screaming bargain. Trailing GAAP P/E of ~37× is meaningless (depressed FY25 GAAP earnings); the operative figure is forward adjusted P/E: ~16.7× FY26E ($17.79) → 15.0× FY27E ($19.81) → 9.6× FY30E ($31.04). Enterprise-value metrics reflect the thin-margin model: EV/Sales 0.21× (as expected for a distributor) and EV/EBITDA 13.6×, roughly fair for a low-growth defensive. A ~17× multiple on FY26E adjusted EPS anchors our ~$340 base case; the mid-teens forward multiple is reasonable for a ~15% EPS compounder with defensive characteristics, and there is room for modest re-rating if OneOncology accretion and buybacks deliver. Street targets (context): consensus $378.57, high $440, low $331 — our base is deliberately below consensus because we discount a thin-margin, leverage-elevated distributor more heavily. Not a value trap, not a deep-value gift — a fair-to-modestly-cheap defensive.
7. Technicals (from the tech block)
- Trend: mixed / repairing. $296.51 sits above the 50-DMA ($279) but below the 200-DMA ($324) — the 200-DMA is the overhead resistance a recovery must reclaim. Not a clean uptrend.
- Location: −20.9% off the 52-week high ($374.75) and +17.3% off the 52-week low ($252.74). Max drawdown from peak ~−21% — a meaningful correction, which is part of the value case.
- Momentum: RSI(14) 66 — firm and near the upper band but not yet overbought (<70); MACD +2.98 (positive), consistent with the recent bounce off the lows.
- Relative strength (the tell): COR +0.4% 12-mo vs SPY +20.6% and QQQ +30.3% — significant underperformance, and −6.7% 3-mo / −12.8% 6-mo while SPY rose. This is a laggard being bought for value/mean-reversion, not a momentum leader.
- Read: technicals are constructive-but-unconfirmed — a name basing after a ~21% drawdown, back above its 50-DMA, with the 200-DMA (~$324) as the line that would confirm a trend change. A value/tactical entry, not a breakout chase.
8. Moat & competitive position
Cencora's moat is scale, logistics density and working-capital efficiency inside a stable US oligopoly (Cencora / McKesson / Cardinal Health control the vast majority of US drug distribution). The barriers are real but the model is structurally low-margin and low-differentiation: switching costs, national delivery networks, supplier relationships and the negative cash-conversion cycle protect the incumbents, but pricing power over manufacturers and payers is limited, and the value captured per dollar of drug is tiny by design. The growth/margin edge is in specialty and oncology distribution (the OneOncology deal), where fees and services are richer.
Peer set (FMP-listed comps, market cap): the FMP peer list is mostly non-comparable (Japanese/European wholesalers Alfresa $2.2B, Galenica $5.7B, Sugi $2.9B, McKesson Europe $5.4B; plus Becton Dickinson $57.3B, Patterson $2.8B, Covetrus, and several micro/OTC shells). The true direct comparables are the other Big Three — McKesson (MCK) and Cardinal Health (CAH) — which are not in this FMP peer list but are the relevant benchmark. Cencora sits mid-pack among them on growth and margin; none of these distributors commands a premium multiple, which is appropriate for the economics.
9. Management, capital allocation & guidance
- Leadership: Robert P. Mauch is President & CEO; Eva C. Boratto is CFO (RSU award filed 2026-06-30).
- Capital allocation: debt-funded M&A (OneOncology, ~$4.3B) to buy margin mix, then deleverage first, buy back second — management's Q2 FY26 release explicitly states it made "progress on debt paydown" and is "in a position to resume opportunistic share repurchases," targeting $1 billion in buybacks by end of calendar 2026. Dividend is modest (~0.8% yield, ~18% payout). This is a disciplined, capital-return-oriented allocation profile appropriate for a low-growth cash generator.
- Insider activity (a genuine positive tell): two open-market director purchases in the recent window — Director Dermot Durcan bought 4,000 shares at $266.26 (2026-05-28) and another 4,000 at $274.19 (2026-06-18); Director Lauren Tyler bought 550 shares at $270.23 (2026-06-22). Directors buying with their own cash below the current price is a modestly bullish signal (the routine RSU awards to the CFO are neutral).
- Management's own guidance (half-weighted — their self-interested words): from the SEC 8-K / Q2 FY26 earnings release (filed 2026-05-06), management raised full-year fiscal-2026 adjusted diluted EPS guidance to $17.65–$17.90 (from $17.45–$17.75). CEO Mauch: "Our fiscal 2026 guidance reflects the strength of our business and focus on our strategy to create long-term value." Treat as management's own book (half-weight); it corroborates the Street's ~$17.79 FY26E and the mid-teens EPS trajectory. Note the raise is modest and largely mix/buyback-driven, not a demand surprise.
10. Catalysts & what to watch
- Next earnings: 2026-08-05 (Q4 FY26; Street adj. EPS $4.39, revenue ~$84.4B). Watch full-year adjusted EPS vs the $17.65–$17.90 guide and any FY27 framing.
- OneOncology accretion: gross-margin lift and specialty/oncology contribution — the key margin-mix swing factor.
- Deleveraging + buyback restart: progress toward net-debt/EBITDA normalization and the $1B end-CY2026 repurchase — a direct EPS lever.
- GLP-1 volume vs margin: high GLP-1 distribution volume boosts revenue but dilutes gross margin — watch the mix.
- Opioid litigation / regulatory: residual liability and any new developments — a tail risk unique to distributors.
Thesis tripwires (what would change the call): a cut to FY26 adjusted-EPS guidance; distribution gross margin compressing below ~3.3%; net-debt/EBITDA rising rather than falling; a material adverse opioid-liability development; or the stock failing to reclaim the 200-DMA on improving fundamentals.
11. Key risks
- Thin-margin fragility (structural): at ~3.5% gross / <1% net margin, tiny changes in distribution economics swing earnings materially — the defining risk of the model.
- Leverage stepped up: net-debt/EBITDA ~2.0× post-OneOncology; deleveraging must proceed before buybacks scale, and higher rates pressure interest expense.
- Opioid & regulatory liability: distributors carry residual opioid-settlement exposure and drug-pricing/policy risk — a sector-specific overhang.
- Customer concentration: large-customer relationships (national pharmacy chains) mean contract renegotiations can pressure fees.
- Growth ceiling / no expert conviction: ~4% top-line growth caps upside, and no Synthos KB expert coverage means less independent validation than our conviction names — a lower-confidence call by construction.
12. Verdict, position sizing & monitoring
Buy — Tactical. Cencora is a defensive, low-beta distribution utility trading ~21% off its high at ~16.7× forward adjusted EPS, with a disciplined mid-teens adjusted-EPS growth path (buybacks + OneOncology margin mix + volume), strong FCF, raised management guidance, and two open-market director purchases below the current price. Our base-case fair value (~$340, +15%) sits below the Street's $378.57 but still offers a reasonable margin over today's price. It is a Tactical, not Core, buy for three honest reasons: (1) no expert coverage in the Synthos KB — zero borrowed conviction; (2) a structurally thin-margin, leverage-elevated model with limited cushion; (3) low exponential potential — this compounds modestly, it does not inflect.
- Sizing: value/satellite sleeve, ~1–3% — a defensive holding to complement growth positions, not a conviction anchor. Scale in on weakness toward the rising 50-DMA.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $296.51.
- Single biggest risk: the wafer-thin margin combined with elevated leverage — any distribution-fee, opioid-liability or rate shock is amplified by the model's lack of cushion.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — there is no expert coverage of COR in the Synthos knowledge base. This note cites no
claim_ids because none exist; the verdict is explicitly fundamentals- and quant-driven. Fabricated conviction is structurally impossible (claim-ID reconciliation), and we do not manufacture it here. - Data as-of: fundamentals 2026-03-31 (Q2 FY26) · estimates & prices 2026-07-02/03 · no expert claims. Forward figures are analyst consensus (FMP), labeled as estimates. EPS growth figures use adjusted (non-GAAP) EPS, the metric management guides to.
- Management caveat: the FY26 adjusted-EPS guidance ($17.65–$17.90) is management's own book, half-weighted by design, sourced from the SEC 8-K earnings release filed 2026-05-06.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").